Iterum Therapeutics plc - Ordinary Share (ITRM)
ITRM moved a median of 0.00% 30 minutes after news, and -1.18% by the close. How ITRM actually reacts to news — the realized, point-in-time move the market made, measured across 168 labeled events over the last three years with zero look-ahead.
ITRM’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 49% | 163 |
| 30-min | 0.00% | 49% | 165 |
| 60-min | -0.84% | 43% | 166 |
| to close | -1.18% | 45% | 163 |
| Middle 50% of ITRM reactions | -3.06% to +2.40% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 168 |
Half of all Iterum Therapeutics plc - Ordinary Share news events land between -3.06% and +2.40% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ITRM moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ITRM's baseline. Nothing else.
Recent ITRM events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Iterum Therapeutics plc For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | +1.45% | -27.71% | |
| Form 8-K Iterum Therapeutics plc For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | +66.67% | +18.67% | |
| Iterum Therapeutics Announces Filing of Winding Up Petition | Press release | GlobeNewswire | +66.67% | +18.67% | |
| Form 8-K Iterum Therapeutics plc For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | -4.27% | +2.74% | |
| Form 8-K Iterum Therapeutics plc For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | -4.42% | -23.68% | |
| Form 8-K Iterum Therapeutics plc For: Feb 18 | SEC filing · Form 8-K | SEC EDGAR | -6.72% | -7.14% | |
| Form DEFA14A Iterum Therapeutics plc | SEC filing · Form DEFA14A | SEC EDGAR | -1.86% | -8.50% | |
| Iterum Therapeutics Provides Business Update | Press release | GlobeNewswire | +5.84% | -3.92% | |
| Form DEFA14A Iterum Therapeutics plc | SEC filing · Form DEFA14A | SEC EDGAR | +3.83% | -0.52% | |
| Form DEF 14A Iterum Therapeutics plc For: Jan 02 | SEC filing · Form DEF | SEC EDGAR | -0.43% | +10.11% | |
| Form PRE 14A Iterum Therapeutics plc For: Dec 23 | SEC filing · Form PRE | SEC EDGAR | -3.13% | -1.84% | |
| Iterum Therapeutics Provides Business Update | Press release | GlobeNewswire | +0.44% | -5.41% | |
| Iterum Therapeutics Provides Business Update | Press release | GlobeNewswire | +0.42% | -2.80% | |
| Form 8-K Iterum Therapeutics plc For: Dec 11 | SEC filing · Form 8-K | SEC EDGAR | +2.22% | -6.44% | |
| Iterum Therapeutics Provides Business Update | Press release | GlobeNewswire | -2.49% | -3.67% | |
| Iterum Therapeutics Provides Business Update | Press release | GlobeNewswire | +0.00% | +5.00% | |
| Form 10-Q Iterum Therapeutics plc For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.38% | -5.98% | |
| Form 8-K Iterum Therapeutics plc For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | +0.38% | -5.98% | |
| Iterum Therapeutics Reports Third Quarter 2025 Financial Results | Press release | GlobeNewswire | +0.38% | -5.98% | |
| Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025 | Press release | GlobeNewswire | +2.72% | +3.60% | |
| Form 8-K Iterum Therapeutics plc For: Oct 16 | SEC filing · Form 8-K | SEC EDGAR | +4.25% | -3.44% | |
| Iterum Therapeutics to Present Data at IDWeek 2025 | Press release | GlobeNewswire | -1.37% | +0.00% | |
| Iterum Therapeutics Provides Business Update | Press release | GlobeNewswire | -0.46% | -4.03% | |
| Form 8-K Iterum Therapeutics plc For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | -5.22% | -5.35% | |
| Form 8-K Iterum Therapeutics plc For: Aug 25 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.91% | |
| Form 8-K Iterum Therapeutics plc For: Aug 20 | SEC filing · Form 8-K | SEC EDGAR | +0.88% | -8.73% | |
| Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S. | Press release | GlobeNewswire | +0.88% | -8.73% | |
| Form 10-Q Iterum Therapeutics plc For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.79% | -2.58% | |
| Form 8-K Iterum Therapeutics plc For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +0.79% | -2.58% | |
| Iterum Therapeutics Reports Second Quarter 2025 Financial Results | Press release | GlobeNewswire | +0.79% | -2.58% | |
| Form 8-K Iterum Therapeutics plc For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | +0.79% | -2.58% | |
| Form DEF 14A Iterum Therapeutics plc For: Jul 28 | SEC filing · Form DEF | SEC EDGAR | -0.61% | — | |
| Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025 | Press release | GlobeNewswire | -0.61% | — | |
| Form 8-K Iterum Therapeutics plc For: Jul 17 | SEC filing · Form 8-K | SEC EDGAR | -1.62% | -5.33% | |
| Form PRE 14A Iterum Therapeutics plc For: Jul 18 | SEC filing · Form PRE | SEC EDGAR | +1.11% | +1.84% | |
| Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.03% | -0.63% | |
| Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth | Press release | GlobeNewswire | -1.97% | -1.49% | |
| Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence | Press release | GlobeNewswire | -0.38% | +4.70% | |
| Form 8-K Iterum Therapeutics plc For: Jun 06 | SEC filing · Form 8-K | SEC EDGAR | +4.67% | -2.80% | |
| Iterum Therapeutics Announces Partnership for Commercialization Services | Press release | GlobeNewswire | +4.67% | -2.80% | |
| Form 8-K Iterum Therapeutics plc For: May 13 | SEC filing · Form 8-K | SEC EDGAR | +0.51% | +0.67% | |
| Iterum Therapeutics Announces Extension of Term of Promissory Note | Press release | GlobeNewswire | +0.51% | +0.67% | |
| Form 10-Q Iterum Therapeutics plc For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.56% | -4.25% | |
| Form 8-K Iterum Therapeutics plc For: May 13 | SEC filing · Form 8-K | SEC EDGAR | -0.56% | -4.25% | |
| Iterum Therapeutics Reports First Quarter 2025 Financial Results | Press release | GlobeNewswire | -0.56% | -4.25% | |
| Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025 | Press release | GlobeNewswire | +0.00% | -2.29% | |
| Form 8-K Iterum Therapeutics plc For: Apr 28 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.67% | |
| Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares | Press release | GlobeNewswire | -1.89% | -5.26% | |
| Iterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary Shares | Press release | GlobeNewswire | +1.96% | +3.92% | |
| Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics | Press release | GlobeNewswire | -0.88% | +0.89% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ITRM section they belong to.
Where else ITRM is measured.
ITRM earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| BODY AND MIND INC (BMMJ) | 168 | 0.00% | 31% |
| Bio-Path Holdings, Inc. (BPTH) | 168 | 0.00% | 43% |
| BIOSTAR PHARMS INC (BSPM) | 167 | 0.00% | 41% |
| Sonoma Pharmaceuticals, Inc. (SNOA) | 167 | -0.32% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Iterum Therapeutics plc - Ordinary Share's median reaction calculated?
Every labeled ITRM news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 168 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 49% of ITRM's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ITRM's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.